PMID- 1431232
OWN - NLM
STAT- MEDLINE
DCOM- 19921207
LR  - 20190723
IS  - 0022-202X (Print)
IS  - 0022-202X (Linking)
VI  - 99
IP  - 5
DP  - 1992 Nov
TI  - Effects of immunomodulatory cytokines on the presentation of tumor-associated 
      antigens by epidermal Langerhans cells.
PG  - 66S-68S
AB  - The recognition and presentation of tumor-associated antigens by cutaneous 
      antigen-presenting cells (APC) may play an important role in the establishment of 
      effective defense mechanisms against newly emerging tumors in the skin. Recent 
      data demonstrate the ability of I-A+ epidermal cells (Langerhans cells) to 
      present tumor-associated antigens for the induction of protective tumor immunity 
      and elicitation of delayed-type hypersensitivity against the murine spindle cell 
      tumor, S1509a. Furthermore, the local cytokine microenvironment in the vicinity 
      of a cutaneous neoplasm may regulate the ability of resident epidermal APC to 
      initiate and/or to elicit protective immunity against incipient cutaneous 
      neoplasms. This article summarizes the effects of 
      granulocyte-macrophage/colony-stimulating factor (GM-CSF), interleukin-1 alpha 
      (IL-1 alpha), tumor necrosis factor-alpha (TNF alpha), transforming growth 
      factor-beta (TGF beta), and interferon-gamma (IFN gamma) on the modulation of 
      antigen presentation by epidermal APC. Our data indicate that these cytokines 
      significantly and differentially modify the ability of epidermal cells to present 
      tumor-associated antigens and that their effects differ with regard to induction 
      of primary immunity (sensitization) or elicitation of secondary immune responses.
FAU - Grabbe, S
AU  - Grabbe S
AD  - Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard 
      Medical School, Boston.
FAU - Bruvers, S
AU  - Bruvers S
FAU - Granstein, R D
AU  - Granstein RD
LA  - eng
GR  - AR40667/AR/NIAMS NIH HHS/United States
GR  - EY07782/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cytokines)
SB  - IM
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Antigen-Presenting Cells/*drug effects
MH  - Antigens, Neoplasm/*immunology
MH  - Cytokines/*pharmacology
MH  - Humans
MH  - Langerhans Cells/drug effects/*immunology
RF  - 28
EDAT- 1992/11/01 00:00
MHDA- 1992/11/01 00:01
CRDT- 1992/11/01 00:00
PHST- 1992/11/01 00:00 [pubmed]
PHST- 1992/11/01 00:01 [medline]
PHST- 1992/11/01 00:00 [entrez]
AID - 0022-202X(92)90727-L [pii]
AID - 10.1111/1523-1747.ep12669018 [doi]
PST - ppublish
SO  - J Invest Dermatol. 1992 Nov;99(5):66S-68S. doi: 10.1111/1523-1747.ep12669018.